RT Journal Article
SR Electronic
T1 Multimodal Diverse Granularity Fusion Network based on US and CT Images for Lymph Node Metastasis Prediction of Thyroid Carcinoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.25.23300117
DO 10.1101/2023.12.25.23300117
A1 Li, Guojun
A1 Yao, Jincao
A1 Peng, Chanjuan
A1 Hu, Yinjie
A1 Zhao, Shanshan
A1 Feng, Xuhan
A1 Yang, Jianfeng
A1 Xu, Dong
A1 Li, Xiaolin
A1 Sha, Chulin
A1 He, Min
YR 2024
UL http://medrxiv.org/content/early/2024/01/05/2023.12.25.23300117.abstract
AB Accurately predicting the risk of cervical lymph node metastasis (LNM) is crucial for surgical decision-making in thyroid cancer patients, and the difficulty in it often leads to over-treatment. Ultrasound (US) and computed tomography (CT) are two primary non-invasive methods applied in clinical practice, but both contain limitations and provide unsatisfactory results. To address this, we developed a robust and explainable multimodal deep-learning model by integrating the above two examinations. Using 3522 US and 7649 CT images from 1138 patients with biopsy-confirmed LNM status, we showed that multimodal methods outperformed unimodal counterparts at both central and lateral cervical sites. By incorporating a diverse granularity fusion module, we further enhanced the area under the curve (AUC) to 0.875 and 0.859 at central and lateral cervical sites respectively. This performance was also validated in an external cohort. Additionally, we quantified the modality-specific contributions for each nodule and systematically evaluated the applicability across various clinical characteristics, aiding in identifying individuals who can benefit most from the multimodal method.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe National Natural Science Foundation of China (No. 82071946) the Natural Science Foundation of Zhejiang Province (No. LZY21F030001) the Pioneer and Leading Goose R&D Program of Zhejiang (No. 2023C04039) the National Key Research and Development Program of China (2022YFF0608403) Youth Research Fund Project of Shaoxing People's Hospital (Grant Number 2022YB07) the fund of Zhejiang Province Medical and Health Science and Technology Project (No. 2023KY581) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Zhejiang Cancer Hospital gave ethical approval for this work Ethics committee of Shaoxing People's Hospital gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThough this study was carried out with participant consent, the dataset remains restricted in public access. For research inquiries, de-identified data can be obtained from the corresponding author upon reasonable request.